Financials Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 16/01/2026			5-day change	1st Jan Change
209,000.00 ^KRW	-0.71%		-3.69%	+15.47%

01-14	Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference	CI
01-06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT

Projected Income Statement: Celltrion, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	1,849	1,891	2,284	2,176	3,557	4,150	5,029	5,774
Change	-	2.26%	20.79%	-4.71%	63.45%	16.65%	21.19%	14.82%
EBITDA ¹	891.4	972.1	873.6	897.2	910.3	1,493	1,974	2,281
Change	-	9.06%	-10.14%	2.7%	1.46%	64.01%	32.21%	15.55%
EBIT ¹	712.1	753.9	647.2	651.5	492	1,156	1,623	1,927
Change	-	5.86%	-14.15%	0.66%	-24.48%	135.02%	40.36%	18.71%
Interest Paid ²	-7,503	-8,238	-7,508	-9,665	-75,572	-65,385	-60,893	-66,760
Earnings before Tax (EBT) ¹	650.7	746.9	626.2	671.1	576.1	1,112	1,588	1,896
Change	-	14.79%	-16.17%	7.17%	-14.15%	93.08%	42.71%	19.44%
Net income ¹	511.3	575.1	533.2	535.6	422.7	868.9	1,248	1,483
Change	-	12.48%	-7.29%	0.47%	-21.09%	105.57%	43.58%	18.86%
Announcement Date	22/02/21	16/02/22	03/03/23	29/02/24	25/02/25	-	-	-

¹KRW in Billions²KRW in Million

Estimates

Fiscal Period: December	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	498.7	457	431.8	401	601.1	550.6	596.1	645.6	510.6	597.5	524	672.3	382.6	737	874.7	881.9	1,064	841.9	961.5	1,026	1,262	1,145	1,243	1,321	1,416
Change	-	-8.37%	-5.51%	-7.14%	49.92%	-8.41%	8.26%	8.32%	-20.91%	17.01%	-12.3%	28.31%	-43.09%	92.63%	18.69%	0.82%	20.6%	-20.85%	14.2%	6.72%	22.97%	-9.27%	8.59%	6.26%	7.19%
EBITDA ¹	-	-	-	-	-	-	-	-	-	-	-	-	-	147	204.7	283.4	275.2	220.4	319.2	374.6	542.2	424	468.8	506.4	582.8
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39.21%	38.42%	-2.89%	-19.92%	44.85%	17.35%	44.75%	-21.8%	10.57%	8.02%	15.08%
EBIT ¹	164.7	207.7	163.2	164	219	142.3	199	213.8	100.6	182.4	183	267.6	18.42	15.44	72.49	207.7	196.4	149.4	242.5	301	450.6	334.1	386	433.2	476.8
Change	-	26.04%	-21.4%	0.47%	33.57%	-35.04%	39.84%	7.44%	-52.93%	81.22%	0.35%	46.25%	-93.12%	-16.21%	369.57%	186.51%	-5.43%	-23.92%	62.27%	24.16%	49.68%	-25.86%	15.55%	12.22%	10.08%
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	100.7	258.4	155.6	187.6	145.2	-	226.8	217.3	48.49	208.2	189.7	282.9	-	-	104.2	178.2	274	195.5	52.43	378	506.3	398	415	462	449
Change	-	156.69%	-39.79%	20.57%	-22.6%	-	-	-4.18%	-77.69%	329.38%	-8.89%	49.12%	-	-	-	71.07%	53.71%	-28.65%	-73.18%	621%	33.95%	-21.4%	4.27%	11.33%	-2.81%
Net income ¹	97.57	-	125.5	135.5	120.5	118.5	183.4	166.7	64.53	166.9	147.5	221.8	1.054	22.44	78.01	85.59	236.6	108.7	61.17	332	399	312.6	277.1	340.8	442.7
Change	-	-	-	7.96%	-11.08%	-1.62%	54.75%	-9.12%	-61.29%	158.61%	-11.61%	50.38%	-99.52%	2,028.84%	247.68%	9.72%	176.48%	-54.08%	-43.71%	442.74%	20.2%	-21.68%	-11.35%	22.99%	29.9%
Announcement Date	22/02/21	12/05/21	13/08/21	10/11/21	16/02/22	12/05/22	05/08/22	09/11/22	03/03/23	08/05/23	14/08/23	07/11/23	29/02/24	09/05/24	07/08/24	08/11/24	25/02/25	09/05/25	20/07/25	20/10/25	-	-	-	-	-

¹KRW in Billions

Estimates

Forecast Balance Sheet: Celltrion, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	100	-476	236	1,310	1,165	1,232	800	-402
Change	-	-576%	149.58%	455.08%	-11.07%	5.71%	-35.06%	-150.25%
Announcement Date	22/02/21	16/02/22	03/03/23	29/02/24	25/02/25	-	-	-

¹KRW in Billions

Estimates

Cash Flow Forecast: Celltrion, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	87.01	63.38	111.2	210	135.1	236.1	316.6	314.5
Change	-	-27.16%	75.4%	88.94%	-35.7%	74.8%	34.09%	-0.66%
Free Cash Flow (FCF) ¹	263,739	589,594	-110,305	327,112	766,812	818,500	1,016,417	1,145,342
Change	-	123.55%	-118.71%	396.55%	134.42%	6.74%	24.18%	12.68%
Announcement Date	22/02/21	16/02/22	03/03/23	29/02/24	25/02/25	-	-	-

¹KRW in Million

Estimates

Forecast Financial Ratios: Celltrion, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	48.21%	51.41%	38.25%	41.22%	25.59%	35.98%	39.25%	39.49%
EBIT Margin (%)	38.51%	39.87%	28.34%	29.93%	13.83%	27.87%	32.27%	33.36%
EBT Margin (%)	35.19%	39.5%	27.42%	30.83%	16.2%	26.81%	31.57%	32.84%
Net margin (%)	27.65%	30.42%	23.34%	24.61%	11.88%	20.94%	24.81%	25.68%
FCF margin (%)	14,262.95%	31,181.9%	-4,829.54%	15,029.76%	21,555.98%	19,724.26%	20,211.07%	19,834.72%
FCF / Net Income (%)	51,582.76%	102,521.45%	-20,688.64%	61,068.54%	181,411.45%	94,195.95%	81,468.3%	77,236%
Profitability
ROA	11.61%	10.7%	9.22%	4.31%	2.14%	4.14%	5.68%	6.32%
ROE	16.68%	16.5%	12.93%	5.07%	2.46%	4.9%	6.84%	7.63%
Financial Health
Leverage (Debt/EBITDA)	0.11x	-	0.27x	1.46x	1.28x	0.83x	0.41x	-
Debt / Free cash flow	0x	-	-0x	0x	0x	0x	0x	-
Capital Intensity
CAPEX / Current Assets (%)	4.71%	3.35%	4.87%	9.65%	3.8%	5.69%	6.29%	5.45%
CAPEX / EBITDA (%)	9.76%	6.52%	12.73%	23.41%	14.84%	15.81%	16.04%	13.79%
CAPEX / FCF (%)	0.03%	0.01%	-0.1%	0.06%	0.02%	0.03%	0.03%	0.03%
Items per share
Cash flow per share ¹	2,253	5,876	5.72	3,447	4,196	6,421	7,797	8,697
Change	-	160.82%	-99.9%	60,152.15%	21.75%	53.02%	21.43%	11.55%
Dividend per Share ¹	-	660.4	-	457.9	721.2	728.4	749.4	814.7
Change	-	-	-	-	57.5%	1.01%	2.89%	8.71%
Book Value Per Share ¹	21,521	25,396	27,510	75,046	81,793	79,211	83,697	88,772
Change	-	18%	8.32%	172.8%	8.99%	-3.16%	5.66%	6.06%
EPS ¹	3,284	3,691	3,530	3,437	1,966	3,787	5,418	6,388
Change	-	12.4%	-4.36%	-2.65%	-42.79%	92.61%	43.05%	17.91%
Nbr of stocks (in thousands)	158,075	158,264	156,488	151,581	223,894	218,797	218,797	218,797
Announcement Date	22/02/21	16/02/22	03/03/23	29/02/24	25/02/25	-	-	-